

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

**VOLUNTARY ANNOUNCEMENT  
APPOINTMENT OF CO-CHIEF FINANCIAL OFFICER**

The board of directors (the “**Board**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from August 23, 2021, Mr. Ming Tu (“**Mr. Tu**”) has been appointed as the Co-Chief Financial Officer and Executive Vice President of the Group reporting to Ms. Christine Lu-Wong, the Chief Financial Officer and Executive Vice President of the Group. Mr. Tu will be primarily responsible for leading all aspects of the Company’s financial strategy, performance, reporting and business planning, as well as functional support, such as treasury, tax, controllership and audit operations.

The biographical details of Mr. Tu are set out below:

Mr. Tu, aged 53, has more than 27 years of experience in management and corporate finance. Prior to joining the Group, Mr. Tu had served as the chief financial officer of General Electric (“**GE**”) China and other senior management positions within GE group for around 24 years at different business units in China, the United States, Japan and other global locations. Since August 2019, he had served as the chief financial officer of the Home Credit China, one of the largest consumer finance companies in China. Mr. Tu obtained a bachelor’s degree in computer science from Fudan University in 1990 and obtained a master of business administration degree in finance and a master of science degree in information systems management from the University of Akron in 1994. He is a graduate of GE’s Executive Financial Leadership Program (**EFLP**) and a certified Six Sigma black belt.

The Board would like to express its warmest welcome to Mr. Tu on his appointment as the Co-Chief Financial Officer and Executive Vice President. With his diverse career in senior financial and operational positions spanning healthcare, services and manufacturing industries, the Company believes that Mr. Tu will contribute to the Company's further development as a leading biologics technology provider.

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, August 24, 2021

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.*

\* *For identification purpose only*